{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T21:19:05Z","timestamp":1787606345946,"version":"build-2736575974"},"reference-count":48,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100018693","name":"H2020","doi-asserted-by":"publisher","award":["851615"],"award-info":[{"award-number":["851615"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["851065"],"award-info":[{"award-number":["851065"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["63\/187969"],"award-info":[{"award-number":["63\/187969"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["2021\/0095296 A1"],"award-info":[{"award-number":["2021\/0095296 A1"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Biotechnology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.tibtech.2026.02.017","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T04:17:10Z","timestamp":1775535430000},"page":"2472-2492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Synthetic RNA\u2013protein decoy granules prevent SARS-CoV-2 infection"],"prefix":"10.1016","volume":"44","author":[{"given":"Or","family":"Willinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naor","family":"Granik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Nelkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai","family":"Salomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0580-7076","authenticated-orcid":false,"given":"Roee","family":"Amit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tibtech.2026.02.017_bb0005","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/s00253-004-1783-3","article-title":"Inhibitors of virus replication: recent developments and prospects","volume":"66","author":"Magden","year":"2005","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.tibtech.2026.02.017_bb0010","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7341493","article-title":"Paxlovid: mechanism of action, synthesis, and in silico study","volume":"2022","author":"Marzi","year":"2022","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.tibtech.2026.02.017_bb0015","series-title":"Profiles of Drug Substances, Excipients and Related Methodology","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/bs.podrm.2022.11.003","article-title":"Chapter three \u2013 remdesivir","volume":"Vol. 48","author":"Bakheit","year":"2023"},{"key":"10.1016\/j.tibtech.2026.02.017_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2021.102329","article-title":"Molnupiravir in COVID-19: a systematic review of literature","volume":"15","author":"Singh","year":"2021","journal-title":"Diabetes Metab. Syndr."},{"key":"10.1016\/j.tibtech.2026.02.017_bb0025","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrd4010","article-title":"Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases","volume":"12","author":"Jordheim","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tibtech.2026.02.017_bb0030","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/jmv.26256","article-title":"Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis","volume":"93","author":"Huang","year":"2021","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.tibtech.2026.02.017_bb0035","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4103\/0253-7613.150308","article-title":"The Tamiflu fiasco and lessons learnt","volume":"47","author":"Gupta","year":"2015","journal-title":"Indian J. Pharmacol."},{"key":"10.1016\/j.tibtech.2026.02.017_bb0040","doi-asserted-by":"crossref","first-page":"D7","DOI":"10.1016\/j.vaccine.2011.06.080","article-title":"The eradication of smallpox \u2013 an overview of the past, present, and future","volume":"29","author":"Henderson","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.tibtech.2026.02.017_bb0045","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00430-016-0451-4","article-title":"Eradication of measles: remaining challenges","volume":"205","author":"Holzmann","year":"2016","journal-title":"Med. Microbiol. Immunol."},{"key":"10.1016\/j.tibtech.2026.02.017_bb0050","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2217\/fmb.15.19","article-title":"Polio vaccination: past, present and future","volume":"10","author":"Bandyopadhyay","year":"2015","journal-title":"Future Microbiol."},{"key":"10.1016\/j.tibtech.2026.02.017_bb0055","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/inthealth\/ihab010","article-title":"Disrupting vaccine logistics","volume":"13","author":"James","year":"2021","journal-title":"Int. Health"},{"key":"10.1016\/j.tibtech.2026.02.017_bb0060","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1001\/jama.2020.6641","article-title":"The equitable distribution of COVID-19 therapeutics and vaccines","volume":"323","author":"Bollyky","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.tibtech.2026.02.017_bb0065","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.3390\/vaccines10081306","article-title":"The race for global equitable access to COVID-19 vaccines","volume":"10","author":"Md Khairi","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.tibtech.2026.02.017_bb0070","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.abf9302","article-title":"Prospective mapping of viral mutations that escape antibodies used to treat COVID-19","volume":"371","author":"Starr","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.tibtech.2026.02.017_bb0075","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1126\/science.abc0870","article-title":"Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2","volume":"369","author":"Chan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.tibtech.2026.02.017_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2021.105147","article-title":"A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency","volume":"194","author":"Leach","year":"2021","journal-title":"Antiviral Res."},{"key":"10.1016\/j.tibtech.2026.02.017_bb0085","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abq6527","article-title":"Optimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants through functional receptor mimicry and treat infection in vivo","volume":"8","author":"Torchia","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.tibtech.2026.02.017_bb0090","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41422-020-00438-w","article-title":"Engineered trimeric ACE2 binds viral spike protein and locks it in \u201cThree-up\u201d conformation to potently inhibit SARS-CoV-2 infection","volume":"31","author":"Guo","year":"2021","journal-title":"Cell Res."},{"key":"10.1016\/j.tibtech.2026.02.017_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2016.10.010","article-title":"Soluble coxsackie- and adenovirus receptor (sCAR-Fc); a highly efficient compound against laboratory and clinical strains of coxsackie-B-virus","volume":"136","author":"Pinkert","year":"2016","journal-title":"Antiviral Res."},{"key":"10.1016\/j.tibtech.2026.02.017_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000360","article-title":"Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state","volume":"5","author":"Haim","year":"2009","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.tibtech.2026.02.017_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1084331","article-title":"Engineered soluble ACE2 receptor: responding to change with change","volume":"13","author":"Li","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2026.02.017_bb0110","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.4049\/jimmunol.1801337","article-title":"Insertion of N-terminal hinge glycosylation enhances interactions of the Fc region of human IgG1 monomers with glycan-dependent receptors and blocks hemagglutination by the influenza virus","volume":"202","author":"Blundell","year":"2019","journal-title":"J. Immunol."},{"key":"10.1016\/j.tibtech.2026.02.017_bb0115","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.4049\/jimmunol.1901145","article-title":"Choice of host cell line is essential for the functional glycosylation of the Fc region of human IgG1 inhibitors of influenza B viruses","volume":"204","author":"Blundell","year":"2020","journal-title":"J. Immunol."},{"key":"10.1016\/j.tibtech.2026.02.017_bb0120","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adi2623","article-title":"An inhaled ACE2 decoy confers protection against SARS-CoV-2 infection in preclinical models","volume":"15","author":"Urano","year":"2023","journal-title":"Sci. Trans. Med."},{"key":"10.1016\/j.tibtech.2026.02.017_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101459","article-title":"Engineered ACE2 decoy in dry powder form for inhalation: a novel therapy for SARS-CoV-2 variants","volume":"33","author":"Ito","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.tibtech.2026.02.017_bb0130","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn7737","article-title":"An engineered ACE2 decoy neutralizes the SARS-CoV-2 Omicron variant and confers protection against infection in vivo","volume":"14","author":"Ikemura","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tibtech.2026.02.017_bb0135","doi-asserted-by":"crossref","first-page":"6811","DOI":"10.1038\/s41467-022-34644-4","article-title":"Formation of synthetic RNA protein granules using engineered phage-coat-protein-RNA complexes","volume":"13","author":"Granik","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tibtech.2026.02.017_bb0140","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1021\/acssynbio.4c00891","article-title":"Formation of polyphasic RNP granules by intrinsically disordered Q\u03b2 coat proteins and hairpin-containing RNA","volume":"14","author":"Granik","year":"2025","journal-title":"ACS Synth. Biol."},{"key":"10.1016\/j.tibtech.2026.02.017_bb0145","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/s41467-021-21578-6","article-title":"Overcoming the design, build, test bottleneck for synthesis of nonrepetitive protein-RNA cassettes","volume":"12","author":"Katz","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tibtech.2026.02.017_bb0150","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1021\/acssynbio.1c00381","article-title":"A cell-free assay for rapid screening of inhibitors of hACE2-receptor-SARS-CoV-2-spike binding","volume":"11","author":"Kikuchi","year":"2022","journal-title":"ACS Synth. Biol."},{"key":"10.1016\/j.tibtech.2026.02.017_bb0155","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.tibtech.2026.02.017_bb0160","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.3390\/ijms22052268","article-title":"Characterization of critical determinants of ACE2\u2013SARS CoV-2 RBD interaction","volume":"22","author":"Brown","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tibtech.2026.02.017_bb0165","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.REV120.015980","article-title":"Priming of SARS-CoV-2S protein by several membrane-bound serine proteinases could explain enhanced viral infectivity and systemic COVID-19 infection","volume":"296","author":"Fuentes-Prior","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tibtech.2026.02.017_bb0170","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40545-022-00411-5","article-title":"Management of COVID-19 vaccines cold chain logistics: a scoping review","volume":"15","author":"Fahrni","year":"2022","journal-title":"J. Pharm. Policy Pract."},{"key":"10.1016\/j.tibtech.2026.02.017_bb0175","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3390\/pharmaceutics14020430","article-title":"Stability modelling of mRNA vaccine quality based on temperature monitoring throughout the distribution chain","volume":"14","author":"Kis","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.tibtech.2026.02.017_bb0180","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.maturitas.2021.05.012","article-title":"Reprint of: the dark side of the moon: global challenges in the distribution of vaccines and implementation of vaccination plans against COVID-19","volume":"150","author":"Mesa-Vieira","year":"2021","journal-title":"Maturitas"},{"key":"10.1016\/j.tibtech.2026.02.017_bb0185","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1016\/j.cell.2021.05.032","article-title":"An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies","volume":"184","author":"Liu","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.tibtech.2026.02.017_bb0190","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1016\/j.cell.2021.06.021","article-title":"In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies","volume":"184","author":"Li","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.tibtech.2026.02.017_bb0195","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.3390\/v15122421","article-title":"Enhancement of SARS-CoV-2 infection via crosslinking of adjacent spike proteins by N-terminal domain-targeting antibodies","volume":"15","author":"Lusiany","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.tibtech.2026.02.017_bb0200","doi-asserted-by":"crossref","DOI":"10.3389\/fmedt.2022.1009451","article-title":"SARS-CoV-2 variants impact RBD conformational dynamics and ACE2 accessibility","volume":"4","author":"Val\u00e9rio","year":"2022","journal-title":"Front. Med. Technol."},{"key":"10.1016\/j.tibtech.2026.02.017_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42003-022-04138-6","article-title":"SARS-CoV-2 spike opening dynamics and energetics reveal the individual roles of glycans and their collective impact","volume":"5","author":"Pang","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.tibtech.2026.02.017_bb0210","doi-asserted-by":"crossref","DOI":"10.1063\/5.0011141","article-title":"Conformational transition of SARS-CoV-2 spike glycoprotein between its closed and open states","volume":"153","author":"Gur","year":"2020","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.tibtech.2026.02.017_bb0215","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe5575","article-title":"Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM","volume":"7","author":"Xu","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.tibtech.2026.02.017_bb0220","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abd4251","article-title":"Distinct conformational states of SARS-CoV-2 spike protein","volume":"369","author":"Cai","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.tibtech.2026.02.017_bb0225","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.3390\/ijms24043774","article-title":"Distinct conformations of SARS-CoV-2 omicron spike protein and its interaction with ACE2 and antibody","volume":"24","author":"Lee","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tibtech.2026.02.017_bb0230","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/s41586-022-04581-9","article-title":"Molecular basis of receptor binding and antibody neutralization of Omicron","volume":"604","author":"Hong","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.tibtech.2026.02.017_bb0235","doi-asserted-by":"crossref","first-page":"4958","DOI":"10.1038\/s41467-022-32665-7","article-title":"Omicron SARS-CoV-2 mutations stabilize spike up-RBD conformation and lead to a non-RBM-binding monoclonal antibody escape","volume":"13","author":"Zhao","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tibtech.2026.02.017_bb0240","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1099\/jgv.0.001453","article-title":"SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology","volume":"101","author":"Ogando","year":"2020","journal-title":"J. Gen. Virol."}],"container-title":["Trends in Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167779926000806?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167779926000806?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T20:24:27Z","timestamp":1787603067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167779926000806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0167779926000806"],"URL":"https:\/\/doi.org\/10.1016\/j.tibtech.2026.02.017","relation":{"has-preprint":[{"id-type":"doi","id":"10.64898\/2026.01.16.699918","asserted-by":"object"}]},"ISSN":["0167-7799"],"issn-type":[{"value":"0167-7799","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthetic RNA\u2013protein decoy granules prevent SARS-CoV-2 infection","name":"articletitle","label":"Article Title"},{"value":"Trends in Biotechnology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tibtech.2026.02.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}